Short answer
Retatrutide is investigational and is not FDA-approved. FDA says it cannot be used in compounding under federal law. It is not a retail treatment that a peptide clinic, med spa, telehealth company, or compounding pharmacy can lawfully offer. Current legitimate access routes are qualifying clinical research and a sponsor-controlled single-patient expanded-access program. Neither route guarantees acceptance or treatment.
What “retatrutide near me” means today
People searching for retatrutide nearby often expect a clinic directory, a prescription appointment, or a local pharmacy. That search does not match the drug’s current legal status. There is no FDA-approved retatrutide product for a clinic to prescribe or a pharmacy to dispense as an approved medication.
Retatrutide, also called LY3437943, activates GIP, GLP-1, and glucagon receptors. Lilly is studying it for obesity and other metabolic conditions. The development program has reached Phase 3, but Phase 3 research is not approval. FDA still has to evaluate a complete application before a product can be marketed for a specific use.
The practical “near me” answer is therefore different: search the federal trial registry for a study that is currently recruiting, or discuss Lilly’s individual expanded-access program with the treating physician responsible for your care. A nearby clinic selling a vial is not the same thing as either pathway.
Why a Phase 3 headline does not create clinic availability
Drug development has separate evidence and regulatory steps. A sponsor can complete a large trial and announce selected results before the complete dataset appears in a medical journal. The sponsor can then use the trial program in a regulatory application. FDA reviews the submitted evidence, manufacturing controls, labeling, and risk-management information before deciding whether to approve a product for a defined use.
TRIUMPH-1 has completed its primary study period, and Lilly has released topline findings. Those facts support continued scientific and regulatory evaluation. They do not authorize commercial prescribing. They also do not validate a vial sold by an unrelated clinic or website. Product identity, manufacturing quality, prescribing information, and post-approval distribution controls cannot be inferred from a study headline.
Current status from four primary sources
| Source | What it establishes | What it does not establish |
|---|---|---|
| FDA drug alert | Retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. | It does not authorize a clinic, telehealth platform, or research seller to market retatrutide. |
| Phase 2 trial | A randomized Phase 2 study included 338 adults. The 12 mg group had a mean 24.2% weight reduction at 48 weeks. Gastrointestinal events were the most common adverse events. | One trial does not prove that a product offered online contains retatrutide or is safe for an individual patient. |
| TRIUMPH-1 registry record | The Phase 3 study is completed, with an actual enrollment of 2,335 and an April 2026 primary completion date. | A completed study is not a recruiting site and does not confer FDA approval. |
| Lilly’s May 2026 release | Lilly reported topline Phase 3 findings and continued development. | A company announcement is not a peer-reviewed publication or an FDA decision. |
How to find a legitimate retatrutide study
ClinicalTrials.gov is the federal registry. Study availability changes, so use the live record rather than a copied list on a marketing site. On July 22, 2026, the registry showed several recruiting studies involving retatrutide, while many larger Phase 3 studies were active but no longer recruiting.
- Open the live search. Use the ClinicalTrials.gov retatrutide results.
- Filter for recruiting studies. “Active, not recruiting” means existing participants may still be followed, not that new participants can enroll.
- Read the condition and eligibility criteria. A study may require a specific condition in addition to obesity or overweight. One currently recruiting study, NCT07035093, also requires chronic low back pain.
- Open Contacts and Locations. Check the site status and use the contact information on the registry record.
- Verify the institution independently. Call the hospital or research organization using a phone number from its own website, then confirm the investigator and trial number.
- Expect informed consent and screening. A legitimate study explains the protocol, risks, alternatives, privacy practices, and right to withdraw.
- Do not pay a broker for the study drug. Payment for a vial is a product sale, not proof of research enrollment.
Study enrollment is selective. A listing can close, a site can stop recruiting, and passing a phone screen does not establish eligibility. Never send medical records to someone who cannot identify the NCT number and research institution.
Expanded access is separate from a clinical trial
ClinicalTrials.gov now lists NCT07629401, a Lilly program for single-patient pre-approval expanded access to retatrutide. The record was first posted June 5, 2026 and was marked available when checked for this guide.
Expanded access is not a retail prescription program. It generally involves a treating physician, sponsor agreement, FDA authorization, institutional review, and patient-specific circumstances. The registry record provides Lilly’s central contact, but it does not publish simple eligibility criteria or promise that a request will be approved. A patient should discuss the program with the physician managing the relevant condition rather than pay an intermediary claiming guaranteed access.
Why a compounding claim is a red flag
FDA’s current statement is direct: retatrutide “cannot be used in compounding under federal law.” The agency explains that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
An FDA warning letter to GenLabMeds provides more detail. Retatrutide has no applicable USP or National Formulary monograph, is not a component of an FDA-approved human drug, and does not appear on the relevant 503A or 503B bulks lists. Products offered as compounded retatrutide therefore did not qualify for those statutory exemptions.
Labels such as “research use only” do not make a consumer sale legitimate. FDA reports that sellers have marketed unapproved products directly to consumers while using research disclaimers and providing instructions for human use. Check the FPC 503A pharmacy guide before relying on a pharmacy or clinic’s marketing language.
Seven seller checks before you share information or money
- Ask whether the offer is a registered study. If yes, require the NCT number and verify it on ClinicalTrials.gov.
- Check the current study status. Completed, withdrawn, and active-not-recruiting records are not open enrollment.
- Confirm the research site. The institution, investigator, and contact must match independent first-party sources.
- Reject “compounded retatrutide” claims. They conflict with FDA’s current public position.
- Reject guaranteed approval or access. Neither a trial nor expanded access guarantees acceptance.
- Protect your health information. Do not upload records to a seller or broker that cannot document its role and privacy safeguards.
- Search FDA enforcement records. Look up the company name in the FDA warning-letter database before relying on its claims.
For broader provider screening, use the peptide clinic verification checklist. It covers clinician licensing, pharmacy identity, monitoring, records, and total cost.
What to discuss with a licensed clinician now
A clinician can explain approved treatment options, contraindications, expected monitoring, and whether research participation is reasonable. Retatrutide headlines should not replace that evaluation. If the immediate goal is weight management rather than research participation, compare clinics based on the exact FDA-approved product, the licensed prescriber, safety screening, follow-up, and full price.
Start with the GLP-1 clinic checklist or the semaglutide clinic guide. Those pages explain what to verify without treating any drug as appropriate for every patient.
Frequently asked questions
Is retatrutide FDA-approved?
No. FDA states that retatrutide has not been found safe and effective for any condition. It remains investigational as of July 22, 2026.
Can a compounding pharmacy make retatrutide?
FDA says retatrutide cannot be used in compounding under federal law. A clinic or pharmacy advertising compounded retatrutide is contradicting the agency’s current published position.
Are any retatrutide trials recruiting?
Yes. ClinicalTrials.gov showed recruiting studies when this guide was checked, but eligibility and site availability vary. Use the live registry, filter by recruiting status, and verify the research institution directly.
What is the retatrutide expanded-access program?
NCT07629401 is Lilly’s listed single-patient pre-approval expanded-access program. It is not a commercial clinic service. A treating physician and the sponsor are central to the request, and access is not guaranteed.
When will retatrutide be available at clinics?
No verified approval date exists. Trial completion, company announcements, regulatory submission, and FDA approval are different events. This guide will be updated when an authoritative source changes the status.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss, current June 15, 2026.
- FDA warning letter to GenLabMeds, September 9, 2025.
- Jastreboff et al., Phase 2 retatrutide trial, New England Journal of Medicine, 2023.
- ClinicalTrials.gov: TRIUMPH-1.
- ClinicalTrials.gov: individual expanded access.
- Lilly: TRIUMPH-1 topline announcement, May 21, 2026.
Editorial note: This guide is educational and does not diagnose, prescribe, or recommend an investigational product. Status was checked on July 22, 2026. Trial records can change. Discuss treatment and research participation with a licensed clinician responsible for your care.